These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 36100142)

  • 1. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
    Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
    Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
    He H; Liu L; Morin EE; Liu M; Schwendeman A
    Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
    Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
    Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine Tumor Targeting.
    Lammers T
    Adv Mater; 2024 Jun; 36(26):e2312169. PubMed ID: 38361435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Abnormality-Oriented Nanomedicine Design.
    Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
    Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer nanomedicines: so many papers and so few drugs!
    Venditto VJ; Szoka FC
    Adv Drug Deliv Rev; 2013 Jan; 65(1):80-8. PubMed ID: 23036224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines for the treatment of hematological malignancies.
    Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
    J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Nanomedicines Based on Synthetic Polypeptides.
    Sun H; Gu X; Zhang Q; Xu H; Zhong Z; Deng C
    Biomacromolecules; 2019 Dec; 20(12):4299-4311. PubMed ID: 31659901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.
    Dawidczyk CM; Kim C; Park JH; Russell LM; Lee KH; Pomper MG; Searson PC
    J Control Release; 2014 Aug; 187():133-44. PubMed ID: 24874289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.
    Balasubramanian V; Liu Z; Hirvonen J; Santos HA
    Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum-based combination nanomedicines for cancer therapy.
    Li Y; Lin W
    Curr Opin Chem Biol; 2023 Jun; 74():102290. PubMed ID: 36989943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
    Qin SY; Zhang AQ; Zhang XZ
    Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy.
    Qin M; Xia H; Xu W; Chen B; Wang Y
    Adv Drug Deliv Rev; 2023 Dec; 203():115137. PubMed ID: 37949414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.